Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27
Katia Coulonval et al.
CELL CYCLE (2022)
CDK4 and CDK6 kinases: From basic science to cancer therapy
Anne Fassl et al.
SCIENCE (2022)
Cyclin-dependent kinases in DNA damage response
Mateusz Kciuk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2022)
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
John Bridgewater et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cell cycle control in cancer
Helen K. Matthews et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Qing Li et al.
CANCER DISCOVERY (2022)
Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
Jiawei Zhang et al.
NATURE COMMUNICATIONS (2022)
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
Orawan Suppramote et al.
FRONTIERS IN ONCOLOGY (2022)
Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
Ziva Pogacar et al.
PLOS ONE (2022)
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Marta Palafox et al.
NATURE COMMUNICATIONS (2022)
Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
Erik S. Knudsen et al.
GUT (2021)
Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Vishnu Kumarasamy et al.
CANCER RESEARCH (2021)
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation
Xinhua Song et al.
JOURNAL OF HEPATOLOGY (2021)
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Analia Azaro et al.
INVESTIGATIONAL NEW DRUGS (2021)
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
Thomas Boerner et al.
HEPATOLOGY (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma
Brent A. Willobee et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
Renata Ferrarotto et al.
CANCER MEDICINE (2021)
Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
Christelle Bouchart et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
CDK4/6 inhibitors: a brief overview and prospective research directions
Tenzin Adon et al.
RSC ADVANCES (2021)
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Xuewei Wu et al.
NATURE CANCER (2021)
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
April C. Watt et al.
NATURE CANCER (2021)
Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells
Ozge Rencuzogullari et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2020)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
Vishnu Kumarasamy et al.
ONCOGENE (2020)
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Beatriz Salvador-Barbero et al.
CANCER CELL (2020)
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Marcus Ruscetti et al.
CELL (2020)
Mammalian cell cycle cyclins
Diego Martinez-Alonso et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
Chu Wu et al.
ONCOTARGETS AND THERAPY (2020)
Quantifying CDK inhibitor selectivity in live cells
Carrow I. Wells et al.
NATURE COMMUNICATIONS (2020)
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
Hera Saqub et al.
SCIENTIFIC REPORTS (2020)
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Christelle Bouchart et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma
Xinhua Song et al.
CLINICAL CANCER RESEARCH (2019)
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N. Primrose et al.
LANCET ONCOLOGY (2019)
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Timothy Kendall et al.
LIVER INTERNATIONAL (2019)
Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
Erik S. Knudsen et al.
ONCOGENE (2019)
Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity
Gunya Sittithumcharee et al.
HEPATOLOGY (2019)
PROTACs- a game-changing technology
Markella Konstantinidou et al.
EXPERT OPINION ON DRUG DISCOVERY (2019)
Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition
Teena Dhir et al.
MOLECULAR CANCER RESEARCH (2019)
Transient Hysteresis in CDK4/6 Activity Underlies Passage of the Restriction Point in G1
Mingyu Chung et al.
MOLECULAR CELL (2019)
Induction chemotherapy in borderline (non-)resectable pancreatic cancer: a unique window of opportunity for understanding pancreatic cancer
Jean-Luc Van Laethem
EUROPEAN JOURNAL OF CANCER (2019)
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Keelan Z. Guiley et al.
SCIENCE (2019)
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
Angela Chou et al.
GUT (2018)
The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells
Noriyoshi Iriyama et al.
LEUKEMIA & LYMPHOMA (2018)
Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Emily M. Cousins et al.
MOLECULAR CANCER RESEARCH (2018)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Filipa Lynce et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy
Melanie Le Duff et al.
CELL DEATH & DISEASE (2018)
A New Strategy to Control and Eradicate Undruggable Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
Robert E. Van Sciver et al.
CANCERS (2018)
Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response
Chao-Yuan Huang et al.
EUROPEAN JOURNAL OF CANCER (2018)
The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium
Alessandra Gentilini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
Radek Jorda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Control of the Restriction Point by Rb and p21
Justin Moser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Shom Goel et al.
TRENDS IN CELL BIOLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Sunkyu Kim et al.
Oncotarget (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Marc Thill et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
B. Colleoni et al.
ONCOGENE (2017)
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan et al.
NATURE COMMUNICATIONS (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Quantitative Cell Cycle Analysis Based on an Endogenous All-in-One Reporter for Cell Tracking and Classification
Thomas Zerjatke et al.
CELL REPORTS (2017)
Cellular Senescence: A Translational Perspective
James L. Kirkland et al.
EBIOMEDICINE (2017)
748TiPABC-06: A RANDOMISED PHASE III, MULTI-CENTRE, OPEN-LABEL STUDY OF ACTIVE SYMPTOM CONTROL (ASC) ALONE OR ASC WITH OXALIPLATIN / 5-FU CHEMOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED / METASTATIC BILIARY TRACT CANCERS (ABC) PREVIOUSLY TREATED WITH CISPLATIN / GEMCITABINE CHEMOTHERAPY.
A. Lamarca et al.
ANNALS OF ONCOLOGY (2017)
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Erik S. Knudsen et al.
TRENDS IN CANCER (2017)
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
Ulrich Luecking et al.
CHEMMEDCHEM (2017)
Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models
Michelle L. Cook Sangar et al.
CLINICAL CANCER RESEARCH (2017)
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Eric Raspe et al.
EMBO MOLECULAR MEDICINE (2017)
Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment
Anna E. Vilgelm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment
Anna E. Vilgelm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
John E. Bisi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences
Charles A. Ishak et al.
MOLECULAR CELL (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson et al.
JAMA ONCOLOGY (2016)
Preoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): Feasibility results and early response monitoring by Diffusion Weighted (DW) MR
Jean-Luc Van Laethem et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Richard S. Finn et al.
BREAST CANCER RESEARCH (2016)
Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer
Natalia J. Sumi et al.
ACS CHEMICAL BIOLOGY (2015)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
Agnieszka K. Witkiewicz et al.
ONCOTARGET (2015)
Genetic Progression of Pancreatic Cancer
Robert W. Cowan et al.
CANCER JOURNAL (2014)
CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
Andreas M. Heilmann et al.
CANCER RESEARCH (2014)
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
Jorge Franco et al.
ONCOTARGET (2014)
A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A
Priya Kadambi Gopalan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
MEK drives cyclin D1 hyperelevation during geroconversion
O. V. Leontieva et al.
CELL DEATH AND DIFFERENTIATION (2013)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Signaling Pathways that Control Cell Proliferation
Robert J. Duronio et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Anne M. Horgan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cdk4/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Fang Liu et al.
MOLECULAR CANCER THERAPEUTICS (2012)
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Gerhard Siemeister et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
Mert Erkan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The meaning of p16ink4a expression in tumors Functional significance, clinical associations and future developments
Agnieszka K. Witkiewicz et al.
CELL CYCLE (2011)
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Tae-Won Kang et al.
NATURE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rb inactivation in cell cycle and cancer The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase
Sabine Paternot et al.
CELL CYCLE (2010)
Targeting the RB-pathway in Cancer Therapy
Erik S. Knudsen et al.
CLINICAL CANCER RESEARCH (2010)
Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
Soren M. Johnson et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Autophagy: cellular and molecular mechanisms
Danielle Glick et al.
JOURNAL OF PATHOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
p27Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes (Publication with Expression of Concern. See vol. 42, 2022)
Arpita Ray et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Several Distinct Polycomb Complexes Regulate and Co-Localize on the INK4a Tumor Suppressor Locus
Goedele N. Maertens et al.
PLOS ONE (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Surgical Outcome and Prognostic Factors in Intrahepatic Cholangiocarcinoma
Toshio Nakagohri et al.
WORLD JOURNAL OF SURGERY (2008)
Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): Its relationship with cyclins and CDK inhibitors
Laurence Bockstaele et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all
Jesus Gil et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
AJ Aguirre et al.
GENES & DEVELOPMENT (2003)
The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells:: activation by TSH, inhibition by TGFO, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis
K Coulonval et al.
EXPERIMENTAL CELL RESEARCH (2003)
Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma
A Tannapfel et al.
JOURNAL OF PATHOLOGY (2002)
Share Paper
